Patrick Amstutz, Ph.D.Chief Executive Officer and Member of the Management Board, Member of the Board of Directors

Patrick Amstutz, Ph.D., has been CEO of Molecular Partners since November 2016. He co-founded Molecular Partners and has been a member of the Company’s management team since its inception in 2004, also holding the positions of CBO and COO. In those roles, Patrick was responsible for business development, alliance management and research and development operations. He has established a wide range of commercial collaborations and licensed several key technologies. In 2022, Patrick was elected President of the Board of Directors of the Swiss Biotech Association. Patrick holds a Master of Science from the ETH Zurich and a Ph.D. in molecular biology from the University of Zurich.

Alexander ZürcherChief Operating Officer and Member of the Management Board

Alexander Zürcher is Chief Operating Officer and a Member of the Management Board of Molecular Partners since 2022. Prior to this role, he served as SVP of Development, where he oversaw project and portfolio management, manufacturing, pharmacology, and quality assurance activities. Alexander has also previously been VP Operations and Director of CMC. He has more than 20 years of industry experience, with prior work in drug development as Director of Drug Product Development at Cytos Biotechnology and Head of R&D Operations at Spirig Pharma. Alexander holds a M.Sc. degree in biology from the University of Basel, as well as certificates in business and project management from the University of Zurich.

Philippe Legenne, M.D., MBAChief Medical Officer

Philippe Legenne, MD, MBA, Chief Medical Officer, joined MP in 2020. Philippe leads the Clinical development and Clinical Operations teams as well as the external scientific engagements to ensure a significant flow of scientific expert insights into the Company. Prior to joining MP, Philippe was leading the oncology and biosimilar Medical team for Amgen in EU and before that, Philippe held positions of growing responsibility in clinical development or Medical Affairs at Novartis, GSK and Janssen in US, UK and Switzerland. Philippe graduated from Medical school in Lille and Business and Health Economics in Paris.

Michael Tobias Stumpp, Ph.D.EVP Projects and Member of the Management Board

Michael Tobias Stumpp, Ph.D., is EVP Projects and a Member of the Management Board of Molecular Partners. Michael is a co-founder of Molecular Partners and was part of the team that invented the DARPin technology. Michael previously served as Chief Scientific Officer of Molecular Partners, in which capacity he oversaw development of the DARPin pipeline. He started his scientific career at the ETH Zurich and then progressed to the Imperial College London and the Tokyo Institute of Technology. Michael has published his research in many international, peer-reviewed scientific journals and presented his findings at numerous congresses.

Renate GloggnerEVP People and Community and Member of the Management Board

Renate Gloggner is EVP People and Community and a Member of the Management Board of Molecular Partners. She joined the Company in October 2021. Prior to joining Molecular Partners, Renate held European and International Human Resource leadership positions at two US companies, Global Blood Therapeutics and Tesaro Bio. In both companies, she built strong teams with an engaging culture in the European headquarter as well as in several European countries, allowing these teams to successfully gain market access and launch products. Renate began her career in biotech at Biogen and Amgen working in a variety of HR roles in the international headquarter as well as in country roles. She holds an MBA from the University of Bern, Switzerland and an executive coaching degree from the University of the West of England, Bristol.

Anne Goubier, D.V.M., Ph.D.SVP Research & Early Development

Anne Goubier, D.V.M., Ph.D., is Senior Vice President, Research & Early Development at Molecular Partners. Anne brings two decades of biotech experience in drug discovery and drug development. She joined Molecular Partners in 2020 and oversees the Biology department, covering the path from target discovery to clinical pharmacology. Prior to joining Molecular Partners, Anne was CSO of Blackbelt Therapeutics, a company she co-started and which was focused on cancer immune metabolism. Before that, she was VP Immunology at Tusk Therapeutics, leading the science and more specifically the development of a first in class non IL-2 blocking CD25 antibody which was acquired by Roche Pharma in 2018. Before Tusk, Anne has held science leadership position in PX Biosolutions, Genticel and Merial. She obtained her doctorate in veterinary medicine from Nantes Veterinary school and her Ph.D. from University Lyon I.

Robert HendriksSVP Finance

Robert Hendriks is Senior Vice President, Finance of Molecular Partners. He joined the company in March 2018 and was appointed VP, Finance in July 2019. Prior to joining Molecular Partners, Robert held finance leadership positions at uniQure of Amsterdam and Veronapharma of London, where he had a leading role in both companies’ U.S. NASDAQ IPO listings and was directly involved in other financing rounds totaling over $500 million. In addition to over 10 years of recent experience in biotech, Robert has over 20 years of experience in international financial management over a wide range of industries and in both public and private companies. Robert holds a degree in business administration from the Erasmus University in Rotterdam, Netherlands, and has attended executive education programs at Wharton School of the University of Pennsylvania and Darden School of Business at the University of Virginia.

Julia Hepp, Ph.D.VP Partnering & Alliance

Julia Hepp, Ph.D., is Vice President, Partnering & Alliances at Molecular Partners. Julia brings two decades of biotech experience in research and development, alliance management and business development to the team. Julia joined Molecular Partners in its early days of pioneering the DARPin technology and is now responsible of the full value chain of business development from partnering, transactions to alliance management. Prior to joining Molecular Partners Julia was Director Project Management at Vivendy Therapeutics and headed Antibody Development at Micromet AG (acquired by Amgen). She obtained her Ph.D. from the Cambridge Centre for Protein Engineering with Sir A. Fersht and did postdoctoral research at University of Zurich in the Lab of Prof Plückthun, already working on the DARPin technology.

Michael PitznerGeneral Counsel & Compliance Officer, SVP Legal and Business Development

Michael Pitzner is General Counsel and Compliance Officer, Senior Vice President of Legal and Business Development at Molecular Partners. He joined the company in November 2022. Prior to joining the team, Michael worked at Novartis Pharma as Global Head Legal for Biologics, Cell & Gene and Contract Manufacturing Organization. Michael also served as Senior Vice President, Head of Legal Affairs and Human Resources at Evolva, a SIX Swiss listed nutrition/life science company in the Basel area. He has a background in private practice in Denmark where he was partner at a leading law firm, Kromann Reumert, co-heading the Healthcare Practice Group. Michael holds a Master of Law from Copenhagen University and a LL.M. in European Intellectual Property Law from Stockholm University.

Seth LewisSVP Investor Relations, Communications and Strategy

Seth Lewis is Senior Vice President, Investor Relations, Communications and Strategy of Molecular Partners. His work includes global communications, shareholder relationship management and external strategy. Prior to joining Molecular Partners, Seth was Head of IR and Communications at Surface Oncology (NASDAQ: SURF) where he was integral in establishing the company’s communications strategy. Prior to Surface, he served as Vice President of IR and Communications at Bavarian Nordic, a Danish-listed, live-virus vaccine developer. He began his career in biotech with the Trout Group (now Solebury Trout), a boutique investor relations and strategic consultancy. Seth obtained a B.A. in history from Hartwick College in Oneonta, NY.

Daniel Steiner, Ph.D.SVP Research & Technology

Daniel Steiner is Senior Vice President, Research & Technology of Molecular Partners. In his previous role with Molecular Partners, Daniel built the department responsible for DARPin generation for all research pipeline projects, specifically establishing the DARPin platform for systemic PK-extension. While earning his Ph.D. at the University of Zurich under Dr. Andreas Plückthun, Daniel established a novel in vitro selection system enabling the efficient selection of DARPins for complex antigens. In addition to his doctorate studies at University of Zurich, Daniel performed his undergraduate studies at the ETH Zürich and at the Imperial College London.

Baris Arican, MBAVP Information Technology

Baris Arican is Vice President of Information Technology and leader of Digitalization at Molecular Partners. Prior to this role, he worked in US and Europe for different Biotech and Pharma companies including more than 20 years at Roche and Genentech. He also led the information technology division of Fagron which is a global pharmaceutical company as group CIO.

Baris is passionate about technology driven innovation and business value creation. He has proven expertise designing and implementing enterprise programs, digital transformation initiatives, cybersecurity, software development, and workforce collaboration. Baris holds an MBA from London Business School in the UK and Master of Computer Science from Bogazici University in Istanbul/Turkey.